U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy in China
SHANGHAI, March 7, 2026 – Jiahui International Cancer Center (JICC) has achieved disease stabilization in a U.S. Patient with advanced non-little cell lung cancer (NSCLC) and Parkinson’s disease using ivonescimab, a novel immunotherapy currently available only in China.1,2,3
Patient’s Journey to Innovative Treatment
The patient, a man in his 70s, had exhausted all standard treatment options at MD Anderson Cancer Center in the United States.1,2,3 His physicians recommended ivonescimab, the first approved bispecific PD-1/VEGF antibody for solid tumors.1,2,4 After a video consultation with Jiahui International Cancer Center in late November – scheduled within a week of his initial inquiry – the patient’s family chose to pursue treatment in Shanghai, citing the center’s multidisciplinary expertise and the experience of its Chief of Medical Oncology, Dr. Xuan Linli, who received her training in the U.S.1,3,4
Treatment Challenges and Success
During treatment, the patient experienced immune-related complications requiring intensive care. JICC rapidly coordinated a multidisciplinary response involving oncology, neurology, critical care, and input from Dr. Zhou Caicun, a principal investigator of ivonescimab.3,4 Following this coordinated care, the patient’s condition stabilized, and ongoing treatment is focused on disease control.3
Jiahui International Cancer Center: A Global Hub for Advanced Cancer Care
Jiahui International Cancer Center, partnered with Massachusetts General Hospital Cancer Center, offers seamless international patient pathways, including remote consultations, travel coordination, and continuous family updates.3,4 The center is experiencing increasing inquiries and referrals from North America, Europe, Asia, and the Middle East, establishing Shanghai as a growing center for advanced cancer care.3
The patient’s daughter expressed gratitude for the dedication and compassion of the entire Jiahui team, including doctors, nurses, support staff, and Ms. Cui, who provided daily bedside care and encouragement.3
About Ivonescimab
Ivonescimab is a novel immunotherapy that functions as a bispecific antibody, binding to both PD-1 (to enhance T-cell activity against tumors) and VEGF (to inhibit tumor blood vessel growth).1 It is currently approved for use in China and is not yet available in the United States.
Contact:
International patient care
[email protected]
WhatsApp: +852 4619 1904
Source:Jiahui International Cancer Center